There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Design, synthesis and evaluation of thienopyridines as ligands of adenosine receptors
Nkomba, Gaofenngwe ; North-West University,2022.
More
Abstract: Despite the availability of various classes of antiepileptic drugs (AEDs), about one third of epileptic patients do not experience satisfactory seizure control with present treatments. This has been an important drive in the search for alternative epilepsy treatment. The endogenous nucleoside adenosine is a known anticonvulsant through activation of adenosine A1 receptors. The development of adenosine derivatives such as N6-cyclohexyladenosine (CHA) as anticonvulsants had limitations which include pronounced peripheral side effects, mainly cardiovascular effects. Over the years, non-nucleoside agonists have been investigated as an alternative set of compounds which are highly potent and selective to specific adenosine receptor (AR) subtypes. The aim of this study was to investigate the use of amino-3,5-dicyanopyridine and thieno[2,3- b]pyridine derivatives as potential A1 AR agonists. A total of 23 test compounds were synthesised (6a–s and 7a–d) and 7 of these were novel (6d and 6k–p), while 4 compounds (7a–d) have been synthesised before but have never been tested for AR affinity. The effect of intramolecular cyclisation that occurs during synthesis of thieno[2,3-b]pyridines from the intermediate compounds, amino-3,5-dicyanopyridines, in relation to AR binding was evaluated. Overall, amino-3,5-dicyanopyridine displayed superior activity towards rA1 ARs compared to thieno[2,3]pyridines. The general poor activity of thieno[2,3-b]pyridines suggest that the intramolecular cyclisation results in molecular stiffening or rigidity which negatively affects binding to the receptors, perhaps, due to steric hindrance. For instance, compound 6f (open ring) had a six-fold better inhibition constant (Ki) value of 48 nM for the A1 subtype compared to its closed ring counterpart compound 7d (rA1Ki = 305 nM). Generally, most amino-3,5- dicyanopyridines exhibited greater affinity toward the rA1 AR (Ki
Keywords: Epilepsy ; Antiepileptic drugs ; Adenosine A1/A2A receptor agonists ; Amino-3 ; 5- dicyanopyridine derivatives ; Thieno[2 ; 3-b]pyridine derivatives ; Intramolecular cyclisation
Purchased from AmBeed: 683-57-8 ; 68470-59-7 ; 123-11-5
CAS No. : | 683-57-8 | MDL No. : | MFCD00008025 |
Formula : | C2H4BrNO | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | JUIKUQOUMZUFQT-UHFFFAOYSA-N |
M.W : | 137.96 | Pubchem ID : | 69632 |
Synonyms : |
|
Signal Word: | Danger | Class: | 8,6.1 |
Precautionary Statements: | P280-P301+P310-P305+P351+P338-P310 | UN#: | 2923 |
Hazard Statements: | H301-H314 | Packing Group: | Ⅱ |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
71% | With potassium carbonate; In N,N-dimethyl-formamide; at 65℃; for 1h; | [0710] 2-Bromoacetamide (0.46 g, 3.4 mmol) was added to methyl 3-fluoro-4- hydroxybenzoate (0.29 g, 1.7 mmol) and potassium carbonate (0.70 g, 5.0 mmol) in DMF (1 mL), and the mixture was heated to 65 °C for lh. The mixture was diluted with EA. and the organic phase was washed with water and brine, dried over anhydrous Na2S0 and concentrated. Compound 380-1 was crystallized from EA and collected by filtration (0.27 g, 71percent). NMR (400 MHz, dmso-i/6): delta 7.67-7.42 (m, 2H), 7.50 (br. s, 1H), 7.38 (br. s, 1H), 7.1 1 (t, J = 8.62, l H), 4.62 (s, 2H), 3.79 (s, 3H). |
[ 2576-47-8 ]
2-Bromoethylamine hydrobromide
Similarity: 0.56
[ 2576-47-8 ]
2-Bromoethylamine hydrobromide
Similarity: 0.56
[ 2576-47-8 ]
2-Bromoethylamine hydrobromide
Similarity: 0.56